Champions Oncology (CSBR) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
XBiotech (XBIT) has outperformed Champions Oncology (CSBR) over the past year, losing 18.2% versus a loss of 23.0%. Over five years, CSBR leads with a -50.6% price change compared with -83.3% for XBIT. Champions Oncology is the larger company by market cap ($69.3 million vs $67.1 million), about 1.0 times the size.
On valuation, XBiotech trades at a lower forward P/E (16.9x vs 49.8x for Champions Oncology).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CSBR | XBIT |
|---|---|---|
| Share price | $4.98 | $2.20 |
| Market cap | $69.31M | $67.07M |
| 1-day change | +2.05% | +0.46% |
| YTD return | -27.93% | -7.95% |
| 1-year return | -23.03% | -18.22% |
| 5-year return | -50.60% | -83.35% |
| Forward P/E | 49.80 | 16.92 |
| EPS (TTM) | $-0.07 | $-1.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.31 | $3.44 |
| 52-week low | $4.59 | $2.09 |
| Distance from 52-week high | -40.07% | -36.05% |
| Average volume | 11.33K | 40.47K |
| Shares outstanding | 13.92M | 30.49M |
| Employees | 214 | 87 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Healthcare · Biotechnology · 214 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Healthcare · Biotechnology · 87 employees
CSBR vs XBIT FAQ
Which is bigger, Champions Oncology or XBiotech?
Champions Oncology (CSBR) is larger, with a market capitalization of $69.31M compared with $67.07M for XBiotech (XBIT).
Which stock has performed better over the past year, CSBR or XBIT?
XBIT returned -18.22% over the past 12 months, compared with -23.03% for CSBR (price return, excluding dividends). Past performance does not predict future results.
Are Champions Oncology and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.